Last reviewed · How we verify
NCT04330846: ENDOCIR
Prospective Multicenter Randomized Comparative Study of the Treatment of de Novo Stenosis in Chron's Disease.
NA trial testing Surgical resection in Crohn Disease in 40 participants. Currently enrolling.
1 April 2026
Quick facts
| Lead sponsor | Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 40 |
| Start date | 29 November 2022 |
| Primary completion | 1 April 2026 |
| Estimated completion | 1 April 2027 |
| Sites | 16 locations across Spain |
Drugs / interventions tested
- Surgical resection
Conditions studied
- Crohn Disease — all drugs for Crohn Disease →
Sponsor
Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa — full company profile →
Who can join
Adults 18 to 80, any sex, with Crohn Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Stenosis is one of the most frequent complications in patients with Crohn's disease (CD), causing greater morbidity and increasing the probability of repeated surgery and short bowel syndrome (1-3). Endoscopic balloon dilation (EBD) is clearly the treatment of choice for short stenoses located at the anastomosis of previous surgeries (4-6). However, there is no scientific evidence for determining the most appropriate treatment for de novo stenosis less than 10 cm in length (surgical versus endoscopic treatment), both in terms of efficacy and complications. Neither has it been established which of these two approaches has a greater impact on the quality of life of patients and on costs.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Endoscopic treatment (endoscopic balloon dilation/self-expandable metal stent) vs surgical resection for the treatment of de novo stenosis in Crohn's disease (ENDOCIR study): an open-label, multicentre, randomized trial.
Loras C, Ruiz-Ramirez P, Romero J, Andújar X, et al · · 2023 · cited 4× · PMID 37365665 · DOI 10.1186/s13063-023-07447-1 -
Interventional endoscopy in inflammatory bowel disease: a comprehensive review.
Pal P, Reddy DN. · · 2024 · cited 1× · PMID 39055373 · DOI 10.1093/gastro/goae075
Verify or expand the search:
- PubMed search for NCT04330846
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Surgical resection
Trials testing the same drug.
- NCT06487481 — Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma · Phase 1 · recruiting
- NCT06908031 — SCRT + mFOLFOX6 + PD-1 Antibody + Targeted Therapy for HIgh-Risk pMMR/MSS Rectal Cancer · Phase 2 · recruiting
- NCT06504381 — DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma · Phase 1, PHASE2 · recruiting
- NCT06575322 — Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Pain, Anxiety and Depressio · recruiting
- NCT06576180 — Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Cognitive Function in Patie · recruiting
Other recruiting trials for Crohn Disease
Currently open trials in the same condition.
- NCT06953791 — Comparison of Quality of Life During a Flare of Crohn's Disease Treated With Prednisolone or aCDED With PEN in Adult Pat · Phase 2 · recruiting
- NCT07310095 — A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD) · Phase 4 · recruiting
- NCT07364734 — Epidemiological Characteristics and Efficacy Evaluation of Difficult-To-Treat Crohn's Disease · recruiting
- NCT07170462 — Cranberry and Gut Health in Crohn's Disease · EARLY_PHASE1 · recruiting
- NCT07196722 — A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease · Phase 2, PHASE3 · recruiting
Other Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa trials
Trials by the same sponsor.
- NCT05698745 — Immunological Characteristics of Preclinical IBD · recruiting
- NCT06469424 — An Active Surveillance, Post-Authorization Study to Characterize the Safety of Tofacitinib in Patients With Moderately t · recruiting
- NCT05271773 — Impact of Therapeutic Intervention on Quality of Life in Patients With Ulcerative Colitis · completed
- NCT06031038 — Impact of Telemonitoring in the Management of Complex IBD in Spain: M-TECCU · NA · completed
- NCT03894228 — Safety of IBD Drugs During Pregnancy and Breastfeeding: Mothers and Babies' Outcomes (DUMBO Registry) · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04330846 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
- Last refreshed: 19 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04330846.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing